PURPOSE: Investigations were carried out to assess the use of tape stripping (TS) for the determination of bioequivalence of topical products containing 1% clotrimazole. METHODS: The study design involved the establishment of an appropriate application time, which was determined by conducting a dose duration study. Subsequently, two bioequivalence studies were conducted: i) using the brand (Canesten Topical - 1% clotrimazole cream) as both the test and the reference product and ii) comparing Canesten cream with a gel product containing the same concentration of clotrimazole (1%). Each tape strip was individually analyzed for clotrimazole content using an HPLC method and Transepidermal Water Loss (TEWL) measurements were used to normalize the stratum corneum thicknesses between subjects. RESULTS: The results of the TS investigations showed that, if the study is sufficiently powered, tape stripping may be used to determine bioequivalence according to the conventional bioequivalence limits of 0.8-1.25, as well as detect formulation differences between different clotrimazole products. CONCLUSIONS: The data from this study provided compelling evidence that tape stripping has the necessary attributes and potential to be used as a tool for the bioequivalence assessment of topical clotrimazole and/or other topical formulations, thereby circumventing the need to undertake expensive and time-consuming clinical trials for such products. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.
PURPOSE: Investigations were carried out to assess the use of tape stripping (TS) for the determination of bioequivalence of topical products containing 1% clotrimazole. METHODS: The study design involved the establishment of an appropriate application time, which was determined by conducting a dose duration study. Subsequently, two bioequivalence studies were conducted: i) using the brand (Canesten Topical - 1% clotrimazole cream) as both the test and the reference product and ii) comparing Canesten cream with a gel product containing the same concentration of clotrimazole (1%). Each tape strip was individually analyzed for clotrimazole content using an HPLC method and Transepidermal Water Loss (TEWL) measurements were used to normalize the stratum corneum thicknesses between subjects. RESULTS: The results of the TS investigations showed that, if the study is sufficiently powered, tape stripping may be used to determine bioequivalence according to the conventional bioequivalence limits of 0.8-1.25, as well as detect formulation differences between different clotrimazole products. CONCLUSIONS: The data from this study provided compelling evidence that tape stripping has the necessary attributes and potential to be used as a tool for the bioequivalence assessment of topical clotrimazole and/or other topical formulations, thereby circumventing the need to undertake expensive and time-consuming clinical trials for such products. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.
Authors: Avraham Yacobi; Vinod P Shah; Edward D Bashaw; Eva Benfeldt; Barbara Davit; Derek Ganes; Tapash Ghosh; Isadore Kanfer; Gerald B Kasting; Lindsey Katz; Robert Lionberger; Guang Wei Lu; Howard I Maibach; Lynn K Pershing; Russell J Rackley; Andre Raw; Chinmay G Shukla; Kailas Thakker; Nathalie Wagner; Elizabeta Zovko; Majella E Lane Journal: Pharm Res Date: 2014-01-07 Impact factor: 4.200
Authors: S F Cordery; A Pensado; W S Chiu; M Z Shehab; A L Bunge; M B Delgado-Charro; R H Guy Journal: Int J Pharm Date: 2017-06-19 Impact factor: 5.875
Authors: Manfred Bodenlenz; Katrin I Tiffner; Reingard Raml; Thomas Augustin; Christian Dragatin; Thomas Birngruber; Denise Schimek; Gerd Schwagerle; Thomas R Pieber; Sam G Raney; Isadore Kanfer; Frank Sinner Journal: Clin Pharmacokinet Date: 2017-01 Impact factor: 6.447
Authors: Leila Bastos Leal; Sarah F Cordery; M Begoña Delgado-Charro; Annette L Bunge; Richard H Guy Journal: Pharm Res Date: 2017-01-17 Impact factor: 4.200